Synthorx Appoints Patrick J. Doyle as Chief Business Officer
SAN DIEGO, November 28, 2016 -- /PRNewswire/ -- Synthorx Inc., a biotechnology company using synthetic biology to discover and develop novel protein therapeutics, announced today the appointment of Patrick J. Doyle as chief business officer.
Synthorx Announces $10 Million Series B Financing to Develop and Scale Novel Protein Therapeutics with Improved Pharmacological Properties
SAN DIEGO, July 20, 2016 -- /PRNewswire/ -- Synthorx Inc. announced today the completion of a $10 million Series B financing, led by RA Capital Management and joined by Series...
Synthorx Advances Its Synthetic DNA Technology To Make Its First Full-Length Proteins Incorporating Novel Amino Acids
Synthorx’s synthetic DNA base pair expands the DNA alphabet to enable the creation of more diverse proteins for wide variety of applications in medicine and technology
SAN DIEGO, August 19, 2015...
Synthorx Launches with Breakthrough Synthetic Biology
First example of in vivo replication of a synthetic DNA base pair published in Nature
In The News
Top News: Synthorx Co-founder Creates Stable Semi-Synthetic Organism
Synthorx co-founder, Floyd Romesberg, Ph.D. and colleagues have created a single-cell organism that can stably maintain a synthetic DNA base pair. The research was published in PNAS.
BioWorld Insight: Taking Novel Drug Development to the Next Level
BioWorld Insight interviewed Synthorx CEO, Court Tuner, to discuss how synthetic biology is being used to take drug development to the next level.
To develop improved drugs, Synthorx is using the...
Synthorx Co-founder, Dr. Floyd Romesberg Presents at TEDMED
Developing the Expanded Genetic Code: G.C.A.T. Those four letters have been the world’s genetic vocabulary since the beginning of life on earth, that is, until Dr. Floyd Romesberg and his team created X and Y.
MIT Technology Review: Startup’s Artificial DNA Could Revolutionize Drug Design
MIT Technology Review interviewed Synthorx president and CEO, Court Turner, to discuss how the company is pursuing breakthrough medicines with proteins unlike any seen in nature.
Proteins are formed by stringing...
Top News: Synthorx Raises $10 Million to Develop and Scale Novel Protein Therapeutics with Improved Pharmacological Properties
In July 2016, Synthorx announced the completion of a $10 million Series B financing, led by RA Capital Management and joined by Series A investors Avalon Ventures and Correlation Ventures. (
National Academy of Sciences: Forum on Synthetic Biology
Dr. Floyd Romesberg speaks at TechnonomyBio Conference at the Computer History Museum in Mountain View.
16th Symposium on Chemistry of Nucleic Acid Components
Dr. Floyd Romesberg presents "Expansion of the Genetic Alphabet" at the 16th Symposium on Chemistry of Nucleic Acid Components in Český Krumlov, Czech Republic.
We will be announcing upcoming events shortly.